Hexarelin · research summary

The cardiovascular action of hexarelin.

Journal of geriatric cardiology : JGC · 2014. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Concise review of current evidence
“In this concise review, we discuss the current evidence for the cardiovascular action of hexarelin.”

Subjects

Experimental animal models (rats, mice) and human volunteers/patients
“However, as current evidence is mainly from experimental animal models or in vitro cell lines, clinical trials aimed to extend the application of hexarelin in human subjects and observe its efficacy and potential side effects are warranted.”

Reported findings

Hexarelin exerts positive inotropic effects, increasing left ventricular ejection fraction and cardiac output.
“Acute intravenous administration of hexarelin (2 µg/kg) induced a rapid increase in LVEF, cardiac output, and cardiac index, while reducing wedge pressure.”
Hexarelin demonstrates cardioprotective effects by reducing infarct size, inhibiting apoptosis, and attenuating cardiac fibrosis.
“Hexarelin treatment of spontaneously hypertensive rats for five weeks significantly reduced cardiac fibrosis by decreasing interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline content, and reducing collagen I and III mRNA and protein expression.”
The cardiovascular actions of hexarelin are mediated by the CD36 receptor and GHSR 1a, independent of growth hormone release.
“These beneficial effects seem to be mediated through the direct binding and activation of its cardiac receptors CD36 and GHSR 1a.”

Limitations stated by the authors

Evidence is primarily from experimental animal models or in vitro cell lines, necessitating clinical trials for human application.
“However, as current evidence is mainly from experimental animal models or in vitro cell lines, clinical trials aimed to extend the application of hexarelin in human subjects and observe its efficacy and potential side effects are warranted.”

Source: PubMed 25278975 · DOI 10.11909/j.issn.1671-5411.2014.03.007 · all study summaries

Subjects

Experimental animal models (rats, mice) and human volunteers/patients

“However, as current evidence is mainly from experimental animal models or in vitro cell lines, clinical trials aimed to extend the application of hexarelin in human subjects and observe its efficacy and potential side effects are warranted.”

Reported findings

Hexarelin exerts positive inotropic effects, increasing left ventricular ejection fraction and cardiac output.

“Acute intravenous administration of hexarelin (2 µg/kg) induced a rapid increase in LVEF, cardiac output, and cardiac index, while reducing wedge pressure.”

Hexarelin demonstrates cardioprotective effects by reducing infarct size, inhibiting apoptosis, and attenuating cardiac fibrosis.

“Hexarelin treatment of spontaneously hypertensive rats for five weeks significantly reduced cardiac fibrosis by decreasing interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline content, and reducing collagen I and III mRNA and protein expression.”

The cardiovascular actions of hexarelin are mediated by the CD36 receptor and GHSR 1a, independent of growth hormone release.

“These beneficial effects seem to be mediated through the direct binding and activation of its cardiac receptors CD36 and GHSR 1a.”

Limitations stated by the authors

Evidence is primarily from experimental animal models or in vitro cell lines, necessitating clinical trials for human application.

“However, as current evidence is mainly from experimental animal models or in vitro cell lines, clinical trials aimed to extend the application of hexarelin in human subjects and observe its efficacy and potential side effects are warranted.”